Biotech Startups
9,893 companies tagged Biotech, with their investors and founders.
Sight develops immune signatures by analyzing live immune cells using AI to generate clinical insights. The company applies proprietary data and machine learning to immune cell analysis for diagnostic and clinical applications.
3 investors
Silvec develops RNA-based therapies to protect trees, vines, and bushes from viral, bacterial, and fungal diseases without modifying the host genome. Its treatments use a proprietary type of RNA and are aimed at agricultural and horticultural crops such as citrus, olive, cacao, and banana trees.
3 investors
Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.
3 investors
Simergent develops medical device systems for regulated healthcare markets, with expertise in peritoneal dialysis and infusion pump technologies. The company is led by engineers with FDA clearance experience and clinical advisory from nephrologists.
3 investors
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples. The company serves research institutions and laboratories conducting genomics and molecular biology research.
3 investors
SiriusXT develops the SXT-100 soft X-ray microscope, a laboratory-based imaging system that produces nanometer-resolution 3D images of fully hydrated intact cells. The instrument serves research institutions and biotech companies studying subcellular structures and cellular biology.
3 investors
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Its research targets conditions affecting longevity, those requiring supportive care, and certain rare diseases.
3 investors
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism. It has entered a global licensing and research collaboration with Eli Lilly and Company.
3 investors
SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins. The company uses its proprietary JUMP70 platform to restore protein homeostasis and deliver disease-modifying treatments.
3 investors
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
3 investors
Solid IO develops a tumor-on-chip platform using organ-on-chip technology and AI to model patient-specific tumor microenvironments for oncology and immunotherapy research. The platform enables pharmaceutical companies, biotech firms, and cancer clinics to predict treatment responses, accelerate drug development, and support precision medicine in cancer care.
3 investors
Cellular Intelligence is a cell therapy company developing engineered cell treatments for diseases, including a Phase 2-ready therapy for Parkinson's disease acquired from Novo Nordisk. The company applies computational biology and synthetic biology approaches to reprogram cellular function.
3 investors
Sonovascular is developing an interventional treatment for venous thromboembolism (VTE) that uses microbubble-mediated cavitation, delivered as a cath lab-based procedure without requiring ICU treatment. The company operates in the cardiovascular medical device space.
3 investors
Sophont develops multimodal foundation models for medicine that integrate data such as clinical history, labs, imaging, pathology, genomics, and wearables to model patient state, predict outcomes, and generate clinical hypotheses. It releases open-weight models with public benchmarks and builds commercial products with pharma, hospital, and medtech partners.
3 investors
Soufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease. The company focuses on creating potent, precise medicines for patients across various disease areas through advanced delivery platforms.
3 investors
SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system. The company's lead candidate, SPVN06, is being evaluated in the PRODYGY clinical trial.
3 investors
Sparxell designs, engineers, and manufactures plant-based colorants using cellulose, including biomimetic pigments, biodegradable glitter, powders, pearls, foils, and specialty shapes such as sequins. Its products are aimed at high-end consumer product applications, offering an alternative to synthetic dyes, mica, and titania.
3 investors
SpectacularCloud is a real-time analytics platform that transforms food testing data into actionable intelligence, offering instant insights, automated compliance tracking, and integration with existing laboratory and enterprise systems. It serves food safety teams and quality assurance operations requiring real-time monitoring and compliance documentation.
3 investors
Spiderwort Biotechnologies is a biotechnology company developing natural, science-based solutions with potential applications across multiple industries.
3 investors
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.
3 investors
Spur Therapeutics develops gene therapy treatments for genetic diseases, aiming to bring genetic medicine therapies to patients worldwide.
3 investors
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
3 investors
Pharma Edge is an investment portfolio focused on equity securities of pharmaceutical and healthcare companies, targeting both the US and Indian markets to capitalize on rising healthcare demand and patent expirations. The portfolio invests across pharmaceutical companies, biotech firms, healthcare services, and insurance sectors.
3 investors
Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways. The company serves life science researchers and laboratories.
3 investors